Subtype
Gastroesophageal Junction Carcinoma
CI-CAN-00005404Explore in graph →
231 active trials9 approved drugs25 evidence items
- NCIt
- C203675
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005404Explore in graph →
Clinical trials
706 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (86)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00165490 | Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer | completed | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 10, 2014 | clinicaltrials |
| NCT01567618 | Dose-dense Biweekly Docetaxel Combined With 5-fluorouracil as First-line Treatment in Advanced Gastric Cancer(DaeMon) | completed | Phase 2 | 39 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Nov 7, 2014 |
| clinicaltrials |
| NCT00991952 | Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | May 26, 2014 | clinicaltrials |
| NCT00183911 | Study of 5-Fluorouracil and Leucovorin and Intra-abdominal Floxuridine Chemoradiation in Patients With Fully Resected Locally Advanced Gastric Adenocarcinoma | completed | Phase 2 | 25 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00719550 | AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer | completed | Phase 1 / Phase 2 | 130 | AmgenINDUSTRY | 0 | Dec 5, 2013 | clinicaltrials |
| NCT00464893 | Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection | completed | Phase 2 | 70 | Neovii BiotechINDUSTRY | 4 | Dec 4, 2013 | clinicaltrials |
| NCT00077545 | 3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction | completed | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT01118845 | Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma | completed | Phase 2 | 63 | SymBio PharmaceuticalsINDUSTRY | 2 | Jul 4, 2013 | clinicaltrials |
| NCT00098527 | FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer | terminated | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00045526 | Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer | completed | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00084604 | Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT01523015 | Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction | unknown | Phase 2 / Phase 3 | 100 | Medical University of LublinOTHER | 1 | Feb 5, 2013 | clinicaltrials |
| NCT00061958 | Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00103324 | S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00737373 | Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer | completed | Phase 2 | 143 | Krankenhaus NordwestOTHER | 1 | Sep 19, 2012 | clinicaltrials |
| NCT01641783 | Efficacy and Safety Study of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer Patients | unknown | Phase 2 | 40 | Yanqiao ZhangOTHER | 0 | Jul 17, 2012 | clinicaltrials |
| NCT01552980 | Efficacy and Safety Study of a Modified SOX Regimen in First-Line Treatment of Unresectable Gastric Adenocarcinoma(mSOX) | unknown | Phase 2 | 30 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Mar 28, 2012 | clinicaltrials |
| NCT01095120 | Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer | unknown | Phase 2 | 27 | Genta IncorporatedINDUSTRY | 2 | Mar 15, 2012 | clinicaltrials |
| NCT00411151 | Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer | completed | Phase 2 | 52 | Johannes Gutenberg University MainzOTHER | 1 | Jan 20, 2011 | clinicaltrials |
| NCT00165191 | Doxorubicin, Cisplatin, 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus | completed | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 28, 2009 | clinicaltrials |
| NCT00352833 | Safety and Efficacy Study With Catumaxomab in Patients After Curative Resection of a Gastric Adenocarcinoma | completed | Phase 2 | 40 | Neovii BiotechINDUSTRY | 1 | Oct 26, 2007 | clinicaltrials |
| NCT00073502 | Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer | completed | Phase 2 | 43 | OSI PharmaceuticalsINDUSTRY | 3 | Feb 22, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Nov 10, 2014source: clinicaltrials